Bms-191011

CAS No.

202821-81-6

MDL No.

MFCD09753285

C₁₆H₁₀ClF₃N₂O₃

370.71

InChI Key

QKOWACXSXTXRKA-UHFFFAOYSA-N

Pack Size	Purity	Price	Availability
10 mg	99%	$79	In Stock
25 mg	99%	$117	In Stock
50 mg	99%	$175	In Stock
100 mg	99%	$287	In Stock
250 mg	99%	$558	In Stock
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

10 mg

99%

$79

In Stock

25 mg

99%

$117

In Stock

50 mg

99%

$175

In Stock

100 mg

99%

$287

In Stock

250 mg

99%

$558

In Stock

Custom synthesis and bulk supply options are available upon request.

Product Information

3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one is a (trifluoromethyl)benzene derivative.

CAS No.	202821-81-6
Product Name	Bms-191011

Acute Toxic

Signal Word:Danger

HCode:H301-H413

PCode:P264-P270-P273-P301+P316-P321-P330-P405-P501

Pricing & Availability

Product Information

Safety Information

Properties

Documentation

Bms-191011

Pricing & Availability

Product Information

Safety Information

Properties

Related Articles

Vasodilation of retinal arterioles induced by activation of BKCa channels is attenuated in diabetic rats.

Role of calcium-activated potassium channels in acetylcholine-induced vasodilation of rat retinal arterioles in vivo.

BMS-191011, an opener of large-conductance Ca2+-activated potassium channels, dilates rat retinal arterioles in vivo.

3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR.

Documentation